Ameriprise
KNSA icon

Ameriprise’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Ameriprise’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Buy
32,571
+816
+3% +$42.3K ﹤0.01% 3057
2026
Q1 		$1.53M Sell
31,755
-361
-1% -$16K ﹤0.01% 3090
2025
Q4 		$1.32M Sell
32,116
-1,430
-4% -$57.4K ﹤0.01% 3210
2025
Q3 		$1.3M Buy
33,546
+1,289
+4% +$41.9K ﹤0.01% 3229
2025
Q2 		$893K Sell
32,257
-5,014
-13% -$128K ﹤0.01% 3317
2025
Q1 		$828K Sell
37,271
-13,805
-27% -$284K ﹤0.01% 3283
2024
Q4 		$1.01M Sell
51,076
-124,245
-71% -$2.84M ﹤0.01% 3232
2024
Q3 		$4.38M Buy
+175,321
New +$4.27M ﹤0.01% 2469
2024
Q2 		– Sell
-117,231
Closed -$2.31M – 3908
2024
Q1 		$2.31M Sell
117,231
-48,054
-29% -$939K ﹤0.01% 2798
2023
Q4 		$2.9M Sell
165,285
-181,582
-52% -$2.98M ﹤0.01% 2686
2023
Q3 		$6.03M Sell
346,867
-24,408
-7% -$411K ﹤0.01% 2143
2023
Q2 		$5.23M Sell
371,275
-237
-0.1% -$3.17K ﹤0.01% 2315
2023
Q1 		$4M Buy
371,512
+14,896
+4% +$196K ﹤0.01% 2467
2022
Q4 		$5.34M Sell
356,616
-17,374
-5% -$253K ﹤0.01% 2244
2022
Q3 		$4.8M Buy
+373,990
New +$4.26M ﹤0.01% 2259
2021
Q2 		– Sell
-1,371,430
Closed -$25.4M – 3931
2021
Q1 		$25.4M Sell
1,371,430
-999,806
-42% -$20.5M 0.01% 1143
2020
Q4 		$41.9M Buy
2,371,236
+235,977
+11% +$4.15M 0.01% 823
2020
Q3 		$32.7M Buy
2,135,259
+646,420
+43% +$12.1M 0.01% 817
2020
Q2 		$37.9M Buy
1,488,839
+837,770
+129% +$17.5M 0.02% 719
2020
Q1 		$10.1M Sell
651,069
-498,509
-43% -$7.8M 0.01% 1381
2019
Q4 		$12.7M Buy
1,149,578
+477,940
+71% +$4.15M 0.01% 1557
2019
Q3 		$5.72M Sell
671,638
-74,372
-10% -$822K ﹤0.01% 2123
2019
Q2 		$10.1M Buy
746,010
+211,385
+40% +$3.28M ﹤0.01% 1726
2019
Q1 		$9.66M Buy
534,625
+231,985
+77% +$4.48M ﹤0.01% 1731
2018
Q4 		$8.5M Sell
302,640
-67,042
-18% -$1.4M ﹤0.01% 1731
2018
Q3 		$9.43M Sell
369,682
-352,609
-49% -$6.86M ﹤0.01% 1903
2018
Q2 		$12.5M Buy
+722,291
New +$13.1M 0.01% 1554

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Ameriprise's KNSA Position: Q2 2026 in Review

Ameriprise increased its Kiniksa Pharmaceuticals (KNSA) stake by 2.6% in Q2 2026, buying an estimated $42.3K and bringing the position to 32,571 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3057.

Ameriprise first reported a position in KNSA in Q2 2018 and has held it in 27 quarters since. The position peaked at $41.9M in Q4 2020. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Ameriprise held 32,571 shares of Kiniksa Pharmaceuticals worth $2.08M as of Q2 2026.
  • Ameriprise bought 816 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $42.3K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3057 holding.
  • Ameriprise first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 27 quarters since.
  • Ameriprise's Kiniksa Pharmaceuticals position peaked at $41.9M in Q4 2020.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.